{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T04:53:49Z","timestamp":1791089629438,"version":"4.1.0"},"reference-count":25,"publisher":"Spandidos Publications","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2026.15880","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T09:45:27Z","timestamp":1790156727000},"page":"1-9","source":"Crossref","is-referenced-by-count":0,"title":["Netupitant\u2011palonosetron combined with dexamethasone for preventing chemotherapy\u2011induced nausea and vomiting in high\u2011risk patients with colorectal cancer receiving moderately emetogenic chemotherapy: A retrospective study"],"prefix":"10.3892","volume":"32","author":[{"given":"Jiwen","family":"Fan","sequence":"first","affiliation":[{"name":"Department of Oncology, Peking University Shenzhen Hospital Affiliated to Shenzhen University, Shenzhen, Guangdong 518036, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Lai","sequence":"additional","affiliation":[{"name":"Nursing Department, Peking University Shenzhen Hospital Affiliated to Shenzhen University, Shenzhen, Guangdong 518036, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boran","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Oncology, Peking University Shenzhen Hospital Affiliated to Shenzhen University, Shenzhen, Guangdong 518036, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meijing","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Oncology, Peking University Shenzhen Hospital Affiliated to Shenzhen University, Shenzhen, Guangdong 518036, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Oncology, Peking University Shenzhen Hospital Affiliated to Shenzhen University, Shenzhen, Guangdong 518036, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Peking University Shenzhen Hospital Affiliated to Shenzhen University, Shenzhen, Guangdong 518036, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gangling","family":"Tong","sequence":"additional","affiliation":[{"name":"Department of Oncology, Peking University Shenzhen Hospital Affiliated to Shenzhen University, Shenzhen, Guangdong 518036, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"key20261004073024_b1-ol-32-5-15880","first-page":"e70067","article-title":"Colorectal cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J Clin"},{"key":"key20261004073024_b2-ol-32-5-15880","doi-asserted-by":"publisher","first-page":"1369442","DOI":"10.3389\/fphar.2024.1369442","article-title":"Research trends on chemotherapy induced nausea and vomiting: A bibliometric analysis","volume":"15","author":"Ning","year":"2024","journal-title":"Front Pharmacol"},{"key":"key20261004073024_b3-ol-32-5-15880","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1186\/s12885-021-08860-y","article-title":"Pooled analysis of combination antiemetic therapy for chemotherapy-induced nausea and vomiting in patients with colorectal cancer treated with oxaliplatin-based chemotherapy of moderate emetic risk","volume":"21","author":"Shimokawa","year":"2021","journal-title":"BMC Cancer"},{"key":"key20261004073024_b4-ol-32-5-15880","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S1470-2045(19)30862-9","article-title":"Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): A multicentre, open-label, phase 3, randomised, controlled trial","volume":"21","author":"Cremolini","year":"2020","journal-title":"Lancet Oncol"},{"key":"key20261004073024_b5-ol-32-5-15880","first-page":"280","article-title":"2020 ASCO, 2023 NCCN, 2023 MASCC\/ESMO, and 2019 CCO: A comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in cancer patients","volume":"32","author":"Kennedy","year":"2024","journal-title":"Support Care Cancer"},{"key":"key20261004073024_b6-ol-32-5-15880","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.ejca.2022.01.028","article-title":"Assessing the impact of antiemetic guideline compliance on prevention of chemotherapy-induced nausea and vomiting: Results of the nausea\/emesis registry in oncology (NERO)","volume":"166","author":"Aapro","year":"2022","journal-title":"Eur J Cancer"},{"key":"key20261004073024_b7-ol-32-5-15880","doi-asserted-by":"publisher","first-page":"806","DOI":"10.2174\/1568009622666220513094352","article-title":"Netupitant-palonosetron (NEPA) for preventing Chemotherapy-induced nausea and Vomiting: From clinical trials to daily practice","volume":"22","author":"Aapro","year":"2022","journal-title":"Curr Cancer Drug Targets"},{"key":"key20261004073024_b8-ol-32-5-15880","doi-asserted-by":"publisher","first-page":"102195","DOI":"10.1016\/j.esmoop.2023.102195","article-title":"2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting","volume":"9","author":"Herrstedt","year":"2024","journal-title":"ESMO Open"},{"key":"key20261004073024_b9-ol-32-5-15880","doi-asserted-by":"publisher","first-page":"e70549","DOI":"10.1002\/cam4.70549","article-title":"NEPA (Netupitant\/Palonosetron) for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly or moderately emetogenic chemotherapy who experienced breakthrough CINV in cycle 1 of chemotherapy: A phase II clinical trial","volume":"14","author":"Navari","year":"2025","journal-title":"Cancer Med"},{"key":"key20261004073024_b10-ol-32-5-15880","first-page":"5310","article-title":"NEPA (netupitant\/palonosetron) for the antiemetic prophylaxis of nausea and vomiting induced by chemotherapy (CINV) with Folfirinox and Folfoxiri even during the COVID-19 pandemic: A real-life study","volume":"25","author":"De Luca","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"key20261004073024_b11-ol-32-5-15880","doi-asserted-by":"publisher","first-page":"4051","DOI":"10.1200\/JCO.24.00099","article-title":"Effect of adding electroacupuncture to standard triple antiemetic therapy on Chemotherapy-Induced nausea and vomiting: A randomized controlled clinical trial","volume":"42","author":"Shen","year":"2024","journal-title":"J Clin Oncol"},{"key":"key20261004073024_b12-ol-32-5-15880","doi-asserted-by":"publisher","first-page":"105094","DOI":"10.1016\/j.ijnurstu.2025.105094","article-title":"Risk prediction model for chemotherapy-induced nausea and vomiting in cancer patients: A systematic review","volume":"168","author":"Wang","year":"2025","journal-title":"Int J Nurs Stud"},{"key":"key20261004073024_b13-ol-32-5-15880","first-page":"238","article-title":"A randomized, double-blind, placebo-controlled trial of olanzapine versus placebo plus ondansetron and dexamethasone for antiemetic prophylaxis in patients receiving oxaliplatin-, irinotecan-, or carboplatin-based chemotherapy","volume":"34","author":"Harikul","year":"2026","journal-title":"Support Care Cancer"},{"key":"key20261004073024_b14-ol-32-5-15880","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.annonc.2025.10.017","article-title":"Personalised antiemetic prophylaxis with NEPA for patients at high risk of chemotherapy-induced nausea and vomiting receiving moderately emetogenic chemotherapy: Results from the randomised, multinational MyRisk trial","volume":"37","author":"Molassiotis","year":"2026","journal-title":"Ann Oncol"},{"key":"key20261004073024_b15-ol-32-5-15880","doi-asserted-by":"publisher","first-page":"101480","DOI":"10.1016\/j.eclinm.2022.101480","article-title":"Aprepitant plus palonosetron versus dexamethasone plus palonosetron in preventing chemotherapy-induced nausea and vomiting in patients with moderate-emetogenic chemotherapy: A randomized, open-label, phase 3 trial","volume":"49","author":"Cheng","year":"2022","journal-title":"EClinicalMedicine"},{"key":"key20261004073024_b16-ol-32-5-15880","doi-asserted-by":"publisher","first-page":"6575","DOI":"10.2147\/CMAR.S254398","article-title":"Efficacy of Olanzapine-Triple antiemetic regimen in patients with gastrointestinal tumor and high risk of Chemotherapy-Induced nausea and vomiting receiving moderately emetogenic chemotherapy: A retrospective study","volume":"12","author":"Wu","year":"2020","journal-title":"Cancer Manag Res"},{"key":"key20261004073024_b17-ol-32-5-15880","doi-asserted-by":"publisher","first-page":"oyae233","DOI":"10.1093\/oncolo\/oyae233","article-title":"Comparative effectiveness of netupitant-palonosetron plus dexamethasone versus aprepitant-based regimens in mitigating chemotherapy-induced nausea and vomiting: A meta-analysis of randomized controlled trials","volume":"30","author":"Luo","year":"2025","journal-title":"Oncologist"},{"key":"key20261004073024_b18-ol-32-5-15880","first-page":"e56447","article-title":"An Open-Label, Single-Arm, multicenter, observational study evaluating the safety and effectiveness of Akynzeo\u00ae in the management of Chemotherapy-induced nausea and vomiting in india","volume":"16","author":"Gupta","year":"2024","journal-title":"Cureus"},{"key":"key20261004073024_b19-ol-32-5-15880","doi-asserted-by":"publisher","first-page":"e1870","DOI":"10.1002\/onco.13888","article-title":"A pragmatic study evaluating NEPA versus aprepitant for prevention of Chemotherapy-Induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy","volume":"26","author":"Zelek","year":"2021","journal-title":"Oncologist"},{"key":"key20261004073024_b20-ol-32-5-15880","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1002\/cam4.2091","article-title":"Fixed combination of oral NEPA (netupitant-palonosetron) for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: Efficacy data from 2 randomized, double-blind phase III studies","volume":"8","author":"Schwartzberg","year":"2019","journal-title":"Cancer Med"},{"key":"key20261004073024_b21-ol-32-5-15880","first-page":"505","article-title":"Prevalence and predictors of long-delayed (>120 h) chemotherapy-induced nausea and vomiting (CINV)-a systematic review and individual patient data meta-analysis","volume":"31","author":"Chow","year":"2023","journal-title":"Support Care Cancer"},{"key":"key20261004073024_b22-ol-32-5-15880","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s00280-020-04200-2","article-title":"A phase 1 pharmacokinetic study of oral NEPA, the fixed combination of netupitant and palonosetron, in Chinese healthy volunteers","volume":"87","author":"Chen","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"key":"key20261004073024_b23-ol-32-5-15880","doi-asserted-by":"publisher","first-page":"3502","DOI":"10.1111\/bph.13646","article-title":"Role of oxidative stress in oxaliplatin-induced enteric neuropathy and colonic dysmotility in mice","volume":"173","author":"McQuade","year":"2016","journal-title":"Br J Pharmacol"},{"key":"key20261004073024_b24-ol-32-5-15880","doi-asserted-by":"publisher","first-page":"1622789","DOI":"10.3389\/fphar.2025.1622789","article-title":"Efficacy of single low-dose dexamethasone with NEPA for the 168 h prevention of highly or moderately emetogenic chemotherapy","volume":"16","author":"He","year":"2025","journal-title":"Front Pharmacol"},{"key":"key20261004073024_b25-ol-32-5-15880","doi-asserted-by":"publisher","first-page":"1709044","DOI":"10.3389\/fphar.2026.1709044","article-title":"Efficacy and safety of cinobufacini capsules combined with oxaliplatin-based chemotherapy for advanced colorectal cancer: A human systematic review and meta-analysis","volume":"17","author":"Wang","year":"2026","journal-title":"Front Pharmacol"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T04:30:30Z","timestamp":1791088230000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2026.15880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":25,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,9,23]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2026.15880","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]}}}